Effectiveness of Percutaneous Celiac Plexus Ablation in the Treatment of Severe Cancer Pain in Upper Abdomen and Evaluation of Health Economics

Abstract

Objective:

To compare the effectiveness, adverse effects, and cost-effectiveness of percutaneous neurolytic celiac plexus block (NCPB) versus traditional medication strategies for the treatment of patients with advanced cancer having severe upper abdominal cancer pain.

Methods:

This retrospective study included 81 patients with advanced upper abdominal cancer admitted to The Sixth People’s Hospital Affiliated to Shanghai Jiaotong University between January 2013 and July 2014. The patients were divided into percutaneous NCPB (treatment) and medication for pain (control) groups. The outcomes were measured in terms of Numeric Rating Scale (NRS) score and Karnofsky Performance Status (KPS) score before treatment and on the 3rd, 7th, 14th, and 28th days posttreatment. The effectiveness and cost-effectiveness of the therapy were assessed using analysis of the health economics.

Results:

The improvements in NRS score (1.42 ± 1.09 vs 4.03 ± 0.96, P < .01) and KPS score (65.55 ± 9.09 vs 63.03 ± 8.961, P < .01) in the treatment group were significantly superior compared to the control group on the 7th day of treatment, followed by no significant difference between the 2 groups on the 14th and the 28th day of treatment. Health economics evaluation revealed that the medicine-specific costs and total health care costs were significantly reduced in the treatment group compared to the control group (P < .05), but no significant differences between the 2 groups (P > .05) were seen in the costs of hospitalization, examinations, and treatment.

Conclusion:

The percutaneous NCPB method shows promising results and better cost-effectiveness for treating patients with advanced cancer having severe upper abdominal pain.

Keywords

cancer pain celiac plexus ablation health economics percutaneous neurolytic celiac plexus block clinical trial upper abdominal pain

Get full access to this article

View all access options for this article.

References

Nersesyan

Slavin

. Current aproach to cancer pain management: availability and implications of different treatment options. Ther Clin Risk Manag. 2007;3(3):381–400.

Leppert

. Pain management in patients with cancer: focus on opioid analgesics. Curr Pain Headache Rep. 2011;15(4):271–279.

Wang

Shang

Qian

Shao

Wang

Zhao

. CT-guided percutaneous neurolytic celiac plexus block technique. Abdom Imaging. 2006;31(6):710–718.

Andrew

Derry

Taylor

Straube

Phillips

. The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Pract. 2014;14(1):79–94.

Song

Ding

. Overview of pharmacoeconomics. Chinese J Pharmacoepidemiol. 1996;5(3):179–183.

Bodrogi

Kalo

. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. British J Pharmacol. 2010;159(7):1367–1373.

Hoskin

. Cancer pain: treatment overview. In: McMahon

Koltzenburg

, eds. Wall and Melzack’s Textbook of Pain. 5 ed. New York, NY: Churchill Livingstone; 2005:1141–1155.

Gress

Schmitt

Sherman

Ciaccia

Ikenberry

Lehman

. Endoscopic ultrasound-guided celiac plexus block for managing abdominal pain associated with chronic pancreatitis: a prospective single center experience. Am. J. Gastroenterol. 2001;96(2):409–416.

Rana

Candido

Raja

Knezevic

. Celiac plexus block in the management of chronic abdominal pain. Curr Pain Headache Rep. 2014;18(2):394.

10.

Yang

Lai

. Assessment of consecutive neurolytic celiac plexus block (NCPB) technique outcomes in the management of refractory visceral cancer pain. Pain Med. 2012;13(4):518–521.

11.

. Health Economics. Beijing, China: China Traditional Chinese Medicine Publishing House; 2010.

12.

Plancarte

Guajardo-Rosas

Reyes-Chiquete

. Management of chronic upper abdominal pain in cancer: transdiscal blockade of the splanchnic nerves. Reg Anesth Pain Med. 2010;35(6):500–506.

13.

Meuser

Pietruck

Radbruch

Stute

Lehmann

Grond

. Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain. 2001;93(3):247–257.

14.

Yoshimoto

Tomiyasu

Saeki

. How do hospital palliative care teams use the WHO guidelines to manage unrelieved cancer pain? A 1-year, multicenter audit in Japan [published online October 5, 2015]. Am J Hosp Palliat Care. 2015.

15.

Situ

Wang

Shao

Zhu

. Assessment and treatment of cancer pain: from Western to Eastern. Ann Palliat Med. 2012;1(1):32–44.

16.

Breivik

Cherny

Collett

. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann. Oncol. 2009;20(8):1420–1433.

17.

Wiesenthal

Moryl

Glare

. Opening the door of your patient’s medicine cabinet: Unexpected outcomes of cancer pain management. J Clin Oncol. 2014;32(15 suppl):e20629.

18.

Naing

Yeoh

Aung

. A meta-analysis of efficacy and tolerability of buprenorphine for the relief of cancer pain. SpringerPlus. 2014;3:87.

19.

Vranken

Zuurmond

Van Kemenade

Dzoljic

. Neurohistopathologic findings after a neurolytic celiac plexus block with alcohol in patients with pancreatic cancer pain. Acta Anaesthesiol. Scand. 2002;46(7):827–830.

20.

Basinski

Stefaniak

Stadnyk

Sheikh

Vingerhoets

. Influence of religiosity on the quality of life and on pain intensity in chronic pancreatitis patients after neurolytic celiac plexus block: case-controlled study. J Relig Health. 2013;52(1):276–284.

21.

Cook

Lanza

Zhou

. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27(12):1224–1232.